Wall Street analysts expect Catalent, Inc. (NYSE:CTLT – Get Rating) to post sales of $1.33 billion for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Catalent’s earnings, with the highest sales estimate coming in at $1.37 billion and the lowest estimate coming in at $1.31 billion. Catalent posted sales of $1.19 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 11.8%. The company is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Catalent will report full-year sales of $4.85 billion for the current financial year, with estimates ranging from $4.82 billion to $4.88 billion. For the next financial year, analysts anticipate that the company will report sales of $5.29 billion, with estimates ranging from $5.21 billion to $5.36 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT – Get Rating) last announced its earnings results on Tuesday, May 3rd. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Catalent had a net margin of 10.72% and a return on equity of 15.07%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the prior year, the company earned $0.78 earnings per share. The business’s revenue was up 20.9% compared to the same quarter last year.
Shares of NYSE:CTLT opened at $100.19 on Friday. The company has a 50-day simple moving average of $101.10 and a 200-day simple moving average of $109.66. Catalent has a one year low of $86.34 and a one year high of $142.64. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.25 and a current ratio of 2.89. The stock has a market capitalization of $17.96 billion, a price-to-earnings ratio of 36.30, a PEG ratio of 1.59 and a beta of 1.44.
Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Catalent by 2.7% in the first quarter. Vanguard Group Inc. now owns 18,971,342 shares of the company’s stock valued at $2,103,921,000 after purchasing an additional 492,071 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Catalent by 4.2% in the first quarter. BlackRock Inc. now owns 15,631,020 shares of the company’s stock valued at $1,733,479,000 after purchasing an additional 632,934 shares in the last quarter. Capital World Investors lifted its holdings in shares of Catalent by 10.6% in the third quarter. Capital World Investors now owns 10,632,004 shares of the company’s stock valued at $1,414,801,000 after purchasing an additional 1,018,902 shares in the last quarter. State Street Corp lifted its holdings in shares of Catalent by 3.8% in the first quarter. State Street Corp now owns 7,126,429 shares of the company’s stock valued at $790,321,000 after purchasing an additional 261,686 shares in the last quarter. Finally, Veritas Asset Management LLP lifted its holdings in shares of Catalent by 15.3% in the first quarter. Veritas Asset Management LLP now owns 6,999,686 shares of the company’s stock valued at $776,265,000 after purchasing an additional 929,400 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.
About Catalent (Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.